Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021 Apr 16;100(15):e25441.
doi: 10.1097/MD.0000000000025441.

Prognostic and clinicopathological significance of miR-638 in cancer patients: A meta-analysis

Lixia Hu  1 , Mengqin Huang, Qianqian Yuan, Fanliang Kong
Affiliations
Meta-Analysis

Prognostic and clinicopathological significance of miR-638 in cancer patients: A meta-analysis

Lixia Hu et al. Medicine (Baltimore). .

Abstract

Introduction: MiR-638 is believed to be involved in human cancers. However, the prognostic value of miR-638 in human carcinomas is controversial and inconclusive. Therefore, we conducted this meta-analysis to investigate the association between miR-638 expression and clinical outcomes in the patients with various cancers.

Methods: We searched Pubmed, Embase, Wanfang, and the China National Knowledge Infrastructure (CNKI) up to September 1, 2020 to identify relevant studies. Hazard ratios (HRs) and odds ratios (ORs) with 95% confidence intervals (CIs) were used to correlate expression of miR-638 with prognosis and clinicopathological features.

Results: A total of 18 studies involving 1886 patients were included in the meta-analysis. The results revealed that low miR-638 expression was significantly correlated with poor overall survival (OS) (HR = 2.09, 95% CI: 1.46-2.98, P < .001), but not with disease-free survival (DFS) (HR = 1.71, 95% CI: 0.31-9.56, P = .540). Subgroup analysis found that low miR-638 expression was associated with worse OS in patients with digestive system cancer (HR = 2.47, 95% CI: 1.85-3.30, P < .001), the reported directly from articles group (HR = 2.12, 95% CI: 1.34-3.33, P < .001), survival curves group (HR = 2.02, 95% CI: 1.07-3.80, P = .029), in studies with sample size ≥100 (HR = 2.12, 95% CI: 1.34-3.35, P = .001), and in studies with sample size <100 (HR = 2.02, 95%CI: 1.09-3.75, P = .025). Moreover, cancer patients with low miR-638 expression were prone to tumor size (OR = 1.47, 95% CI: 1.03-2.09, P = .035), earlier lymph node metastasis (present vs absent, OR = 2.26, 95% CI: 1.63-3.14, P < .001), earlier distant metastasis (present vs absent, OR = 2.60, 95% CI: 1.45-4.67, P < .001), TNM stage (III-IV vs I-II, OR = 2.01, 95% CI: 1.35-2.99, P = .001), and portal vein invasion (present vs absent, OR = 4.39, 95% CI:2.23-8.64, P < .001), but not associated with age, gender, tumor differentiation, and vascular invasion.

Conclusions: MiR-638 may serve as a promising indicator in the prediction of prognosis and clinicopathological features in patients with different kinds of cancers.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interests to disclose.

Figures

Figure 1
Figure 1
Flow diagram of the literature selection process.
Figure 2
Figure 2
Forest plot of HRs for correlation between miR-638 expression and overall survival (OS).
Figure 3
Figure 3
Forest plot of HRs for correlation between miR-638 expression and disease-free survival (DFS).
Figure 4
Figure 4
Subgroup analysis of the HR of overall survival (OS) by cancer type.
Figure 5
Figure 5
Subgroup analysis of the HR of overall survival (OS) by HR obtain method.
Figure 6
Figure 6
Subgroup analysis of the HR of overall survival (OS) by sample size.
Figure 7
Figure 7
Sensitivity analysis of miR-638 expression and overall survival (OS).
Figure 8
Figure 8
Begg funnel plots for the studies included in meta-analysis. OS (A) and DFS (B).
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020;70:07–30. - PubMed
    1. Urakawa S, Makino T, Yamasaki M, et al. . Lymph node response to neoadjuvant chemotherapy as an independent prognostic factor in metastatic esophageal cancer. Ann Surg 2019;Online ahead of print. - PubMed
    1. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281–97. - PubMed
    1. Chen K, Rajewsky N. The evolution of gene regulation by transcription factors and microRNAs. Nat Rev Genet 2007;8:93–103. - PubMed
    1. Lin SL, Chang DC, Ying SY, et al. . MicroRNA miR-302 inhibits the tumorigenecity of human pluripotent stem cells by coordinate suppression of the CDK2 and CDK4/6 cell cycle pathways. Cancer Res 2010;70:9473–82. - PubMed